The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.

摘要: Aim To evaluate predictive factors which associated with oncological outcomes to first-line axitinib for metastatic renal cell carcinoma (mRCC). Methods A retrospective chart review was conducted patients who had been treated as therapy the treatment of mRCC from September 2013 February 2018. Axitinib given by single daily oral administration at a dose 10 mg, reduced according adverse events (AEs). We investigated progression-free survival (PFS), overall (OS), objective response rate (ORR) and AEs. Results Thirty-eight were enrolled. The median follow-up duration 11.3 months (range = 1.0-56.9). ORR 28.9%. Median PFS OS 12.8, 17.9 months, respectively. In univariate analysis, baseline lactate dehydrogenase (LDH), neutrophil, corrected calcium (Ca), platelets (Plt) time diagnosis selected potential factors. Multivariate Cox's proportional hazards model analysis showed that number risk (P 0.03) 0.02). Conclusion Baseline LDH, Ca, Plt are both in carcinoma.